TY - JOUR
T1 - The Utility of the Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Assay in Detecting Abnormalities in Lipid Metabolism and Cardiovascular Risk in an HIV-Infected South African Cohort
AU - Mayne, Elizabeth S
AU - Moabi, Hellen
AU - Grobbee, Diederick E
AU - Barth, Roos E
AU - Klipstein-Grobusch, Kerstin
AU - Stevens, Wendy S
AU - Vos, Alinda G
AU - Louw, Susan
N1 - Funding Information:
Technical support was provided by Kat Medical (Mr Keith Dodkins), Ms Nomampondo Camane (Roche), and Dr Agnes Magwete. The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by the Discovery Foundation Academic Excellence award (Dr Elizabeth S. Mayne) and a Thuthuka Grant from the South African National Research Foundation (TTK20110801000022866) awarded to Dr Elizabeth S. Mayne.
Publisher Copyright:
© The Author(s) 2019.
PY - 2019/11/5
Y1 - 2019/11/5
N2 - People with HIV (PWH) have an increased prevalence of cardiovascular disease (CVD) compared to uninfected patients. Lipoprotein-associated phospholipase A
2 (Lp-PLA
2) catalyzes the synthesis of pro-inflammatory lipids that recruit monocytes. Current guidelines for assessing cardiovascular risk in HIV-infected patients suggest that Lp-PLA
2 may be a useful surrogate marker for CVD health in this patient population. Lipoprotein-associated phospholipase A
2, lipids, glucose, physical parameters, and carotid intimal–medial thickness (CIMT) were measured in 98 participants (49 HIV-uninfected, 27 antiretroviral therapy [ART]-naive PWH, and 22 ART-treated PWH). HIV viral load (VL) and CD4+ T-cell count were measured in HIV-infected participants. Lipoprotein-associated phospholipase A
2 was increased in participants on protease inhibitor (PI) ART (median 50.5 vs 127.0 nmol/mL, P =.05) and correlated with age, body mass index, and cholesterol. Lipoprotein-associated phospholipase A
2 was not related to Framingham risk score or CIMT but correlated directly with VL (r =.323, P =.025) and inversely with CD4+ T-cell count (r = −.727, P <.001). Lipoprotein-associated phospholipase A
2 was increased in HIV-infected participants on PIs and correlated strongly with VL and CD4+ T-cell count suggesting that HIV-associated inflammation is linked to increased Lp-PLA
2, providing a mechanistic link between HIV and CVD.
AB - People with HIV (PWH) have an increased prevalence of cardiovascular disease (CVD) compared to uninfected patients. Lipoprotein-associated phospholipase A
2 (Lp-PLA
2) catalyzes the synthesis of pro-inflammatory lipids that recruit monocytes. Current guidelines for assessing cardiovascular risk in HIV-infected patients suggest that Lp-PLA
2 may be a useful surrogate marker for CVD health in this patient population. Lipoprotein-associated phospholipase A
2, lipids, glucose, physical parameters, and carotid intimal–medial thickness (CIMT) were measured in 98 participants (49 HIV-uninfected, 27 antiretroviral therapy [ART]-naive PWH, and 22 ART-treated PWH). HIV viral load (VL) and CD4+ T-cell count were measured in HIV-infected participants. Lipoprotein-associated phospholipase A
2 was increased in participants on protease inhibitor (PI) ART (median 50.5 vs 127.0 nmol/mL, P =.05) and correlated with age, body mass index, and cholesterol. Lipoprotein-associated phospholipase A
2 was not related to Framingham risk score or CIMT but correlated directly with VL (r =.323, P =.025) and inversely with CD4+ T-cell count (r = −.727, P <.001). Lipoprotein-associated phospholipase A
2 was increased in HIV-infected participants on PIs and correlated strongly with VL and CD4+ T-cell count suggesting that HIV-associated inflammation is linked to increased Lp-PLA
2, providing a mechanistic link between HIV and CVD.
KW - biomarker
KW - cardiovascular disease
KW - HIV
KW - Lp-PLA
KW - viral load
UR - https://www.scopus.com/pages/publications/85074546609
U2 - 10.1177/1076029619883944
DO - 10.1177/1076029619883944
M3 - Article
C2 - 31686546
SN - 1076-0296
VL - 25
SP - 1
EP - 5
JO - Clinical and Applied Thrombosis/Hemostasis
JF - Clinical and Applied Thrombosis/Hemostasis
ER -